“Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s441. Accessed April 4, 2025. https://skin.dermsquared.com/skin/article/view/3139.